---
title: "Jupiter Neurosciences, Inc. (JUNS.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/JUNS.US.md"
symbol: "JUNS.US"
name: "Jupiter Neurosciences, Inc."
industry: "Pharmaceuticals"
---

# Jupiter Neurosciences, Inc. (JUNS.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | US Market |
| Website | [jupiterneurosciences.com](https://jupiterneurosciences.com) |

## Company Profile

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease tha...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.62 | 145/256 | - | - | - |
| PB | 346.50 | 192/256 | 516.90 | 36.13 | 8.86 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-08-22T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.58 |
| Highest Target | 30.00 |
| Lowest Target | 30.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/JUNS.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/JUNS.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/JUNS.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.